Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Charming Shoppes Q4 Loss Reduces - Quick Facts

Charming Shoppes Inc. (CHRS: Quote) posted a narrower fourth quarter GAAP net loss of 13.2 million or $0.11 per share compared with $30.4 million or $0.26 per share loss a year ago. On a non-GAAP basis, net loss also narrowed to $0.06 per share from last year's $0.08 per share, both periods excluding restructuring and other items. On average, 4 analysts polled by Thomson Reuters expected loss per share of $0.02 for the quarter. Analysts' estimates typically exclude one-time items.

Net sales were $559.1 million for the recent quarter, a 2.9% decrease from $575.8 million in the prior-year period. The $16.7 million decrease includes the impact of operating 207 fewer stores than in the previous year, partially offset by a consolidated comparable-store sales rise of 1%. Three analysts estimated revenues of $542.27 million for the quarter.

Click here to receive FREE breaking news email alerts for Charming Shoppes Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks came under pressure in early trading on Friday and remained firmly in the red throughout the remainder of the trading session. With the losses on the day, the S&P 500 pulled back well off yesterday's record closing high. President Barack Obama is meeting with presidents from Central American nations on Friday as the U.S. struggles to deal with a surge of unaccompanied children across the southern border. Despite calls from some leading conservatives, the results of a new CNN/ORC International poll released Friday showed that a vast majority of Americans do not believe that President Barack Obama should be impeached and removed from office.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.